Martín Igor Gómez-Randulfe: Happy to Share Our New Review on Evolving Treatment for Advanced EGFR Mutated NSCLC
Martín Igor Gómez-Randulfe, Locum Consultant in Lung and Acute Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Happy to share our new review on evolving treatment for advanced EGFR mutated non small cell lung cancer, now live in Critical Reviews in Oncology and Hematology.
• From single agent osimertinib to combinations with chemotherapy, anti angiogenic agents and the amivantamab plus lazertinib doublet, we map the current first line playbook
• Post progression pathways include antibody drug conjugates and the MARIPOSA-2 regimen
• Emphasis on precision sequencing through dynamic ctDNA tracking and CNS active options to stay ahead of resistance
Thanks to all co-authors: Federico Monaca, Raffaele Califano, David Planchard, Emilio Bria.”
Title: Evolving treatment for advanced Non-small cell lung cancer harbouring common EGFR activating mutations
Journal: Critical Reviews in Oncology/Hematology
Authors: Martín Igor Gómez-Randulfe, Federico Monaca, Raffaele Califano, David Planchard, Emilio Bria
MOre posts featuring NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023